Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide

Julio D. Duarte, Issam Zineh, Ben Burkley, Yan Gong, Taimour Y. Langaee, Stephen T Turner, Arlene B. Chapman, Eric Boerwinkle, John G. Gums, Rhonda M. Cooper-DeHoff, Amber L. Beitelshees, Kent R Bailey, Roger B. Fillingim, Bruce C. Kone, Julie A. Johnson

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: Nearly one-third of the United States adult population suffers from hypertension. Hydrochlorothiazide (HCTZ), one of the most commonly used medications to treat hypertension, has variable efficacy. The renal epithelial sodium channel (ENaC) provides a mechanism for fine-tuning sodium excretion, and is a major regulator of blood pressure homeostasis. DOT1L, MLLT3, SIRT1, and SGK1 encode genes in a pathway that controls methylation of the histone H3 globular domain at lysine 79 (H3K79), thereby modulating expression of the ENaCα subunit. This study aimed to determine the role of variation in these regulatory genes on blood pressure response to HCTZ, and secondarily, untreated blood pressure.Methods: We investigated associations between genetic variations in this candidate pathway and HCTZ blood pressure response in two separate hypertensive cohorts (clinicaltrials.gov NCT00246519 and NCT00005520). In a secondary, exploratory analysis, we measured associations between these same genetic variations and untreated blood pressure. Associations were measured by linear regression, with only associations with P ≤ 0.01 in one cohort and replication by P ≤ 0.05 in the other cohort considered significant.Results: In one cohort, a polymorphism in DOT1L (rs2269879) was strongly associated with greater systolic (P = 0.0002) and diastolic (P = 0.0016) blood pressure response to hydrochlorothiazide in Caucasians. However, this association was not replicated in the other cohort. When untreated blood pressure levels were analyzed, we found directionally similar associations between a polymorphism in MLLT3 (rs12350051) and greater untreated systolic (P < 0.01 in both cohorts) and diastolic (P < 0.05 in both cohorts) blood pressure levels in both cohorts. However, when further replication was attempted in a third hypertensive cohort and in smaller, normotensive samples, significant associations were not observed.Conclusions: Our data suggest polymorphisms in DOT1L, MLLT3, SIRT1, and SGK1 are not likely associated with blood pressure response to HCTZ. However, a possibility exists that rs2269879 in DOT1L could be associated with HCTZ response in Caucasians. Additionally, exploratory analyses suggest rs12350051 in MLLT3 may be associated with untreated blood pressure in African-Americans. Replication efforts are needed to verify roles for these polymorphisms in human blood pressure regulation.

Original languageEnglish (US)
Article number56
JournalJournal of Translational Medicine
Volume10
Issue number1
DOIs
StatePublished - Mar 22 2012

Fingerprint

Hydrochlorothiazide
Methylation
Blood pressure
Regulator Genes
Genes
Blood Pressure
Polymorphism
Pressure regulation
Hypertension
Epithelial Sodium Channels
Linear regression
African Americans
Histones
Lysine
Linear Models
Homeostasis
Tuning
Sodium
Association reactions

Keywords

  • Blood pressure
  • DOT1L
  • Histone methylation
  • Hydrochlorothiazide
  • Hypertension
  • MLLT3
  • Pharmacogenetics
  • Pharmacogenomics
  • SGK1
  • SIRT1

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide. / Duarte, Julio D.; Zineh, Issam; Burkley, Ben; Gong, Yan; Langaee, Taimour Y.; Turner, Stephen T; Chapman, Arlene B.; Boerwinkle, Eric; Gums, John G.; Cooper-DeHoff, Rhonda M.; Beitelshees, Amber L.; Bailey, Kent R; Fillingim, Roger B.; Kone, Bruce C.; Johnson, Julie A.

In: Journal of Translational Medicine, Vol. 10, No. 1, 56, 22.03.2012.

Research output: Contribution to journalArticle

Duarte, JD, Zineh, I, Burkley, B, Gong, Y, Langaee, TY, Turner, ST, Chapman, AB, Boerwinkle, E, Gums, JG, Cooper-DeHoff, RM, Beitelshees, AL, Bailey, KR, Fillingim, RB, Kone, BC & Johnson, JA 2012, 'Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide', Journal of Translational Medicine, vol. 10, no. 1, 56. https://doi.org/10.1186/1479-5876-10-56
Duarte, Julio D. ; Zineh, Issam ; Burkley, Ben ; Gong, Yan ; Langaee, Taimour Y. ; Turner, Stephen T ; Chapman, Arlene B. ; Boerwinkle, Eric ; Gums, John G. ; Cooper-DeHoff, Rhonda M. ; Beitelshees, Amber L. ; Bailey, Kent R ; Fillingim, Roger B. ; Kone, Bruce C. ; Johnson, Julie A. / Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide. In: Journal of Translational Medicine. 2012 ; Vol. 10, No. 1.
@article{458a88eb9c334c4b97c73523f8f6c95c,
title = "Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide",
abstract = "Background: Nearly one-third of the United States adult population suffers from hypertension. Hydrochlorothiazide (HCTZ), one of the most commonly used medications to treat hypertension, has variable efficacy. The renal epithelial sodium channel (ENaC) provides a mechanism for fine-tuning sodium excretion, and is a major regulator of blood pressure homeostasis. DOT1L, MLLT3, SIRT1, and SGK1 encode genes in a pathway that controls methylation of the histone H3 globular domain at lysine 79 (H3K79), thereby modulating expression of the ENaCα subunit. This study aimed to determine the role of variation in these regulatory genes on blood pressure response to HCTZ, and secondarily, untreated blood pressure.Methods: We investigated associations between genetic variations in this candidate pathway and HCTZ blood pressure response in two separate hypertensive cohorts (clinicaltrials.gov NCT00246519 and NCT00005520). In a secondary, exploratory analysis, we measured associations between these same genetic variations and untreated blood pressure. Associations were measured by linear regression, with only associations with P ≤ 0.01 in one cohort and replication by P ≤ 0.05 in the other cohort considered significant.Results: In one cohort, a polymorphism in DOT1L (rs2269879) was strongly associated with greater systolic (P = 0.0002) and diastolic (P = 0.0016) blood pressure response to hydrochlorothiazide in Caucasians. However, this association was not replicated in the other cohort. When untreated blood pressure levels were analyzed, we found directionally similar associations between a polymorphism in MLLT3 (rs12350051) and greater untreated systolic (P < 0.01 in both cohorts) and diastolic (P < 0.05 in both cohorts) blood pressure levels in both cohorts. However, when further replication was attempted in a third hypertensive cohort and in smaller, normotensive samples, significant associations were not observed.Conclusions: Our data suggest polymorphisms in DOT1L, MLLT3, SIRT1, and SGK1 are not likely associated with blood pressure response to HCTZ. However, a possibility exists that rs2269879 in DOT1L could be associated with HCTZ response in Caucasians. Additionally, exploratory analyses suggest rs12350051 in MLLT3 may be associated with untreated blood pressure in African-Americans. Replication efforts are needed to verify roles for these polymorphisms in human blood pressure regulation.",
keywords = "Blood pressure, DOT1L, Histone methylation, Hydrochlorothiazide, Hypertension, MLLT3, Pharmacogenetics, Pharmacogenomics, SGK1, SIRT1",
author = "Duarte, {Julio D.} and Issam Zineh and Ben Burkley and Yan Gong and Langaee, {Taimour Y.} and Turner, {Stephen T} and Chapman, {Arlene B.} and Eric Boerwinkle and Gums, {John G.} and Cooper-DeHoff, {Rhonda M.} and Beitelshees, {Amber L.} and Bailey, {Kent R} and Fillingim, {Roger B.} and Kone, {Bruce C.} and Johnson, {Julie A.}",
year = "2012",
month = "3",
day = "22",
doi = "10.1186/1479-5876-10-56",
language = "English (US)",
volume = "10",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide

AU - Duarte, Julio D.

AU - Zineh, Issam

AU - Burkley, Ben

AU - Gong, Yan

AU - Langaee, Taimour Y.

AU - Turner, Stephen T

AU - Chapman, Arlene B.

AU - Boerwinkle, Eric

AU - Gums, John G.

AU - Cooper-DeHoff, Rhonda M.

AU - Beitelshees, Amber L.

AU - Bailey, Kent R

AU - Fillingim, Roger B.

AU - Kone, Bruce C.

AU - Johnson, Julie A.

PY - 2012/3/22

Y1 - 2012/3/22

N2 - Background: Nearly one-third of the United States adult population suffers from hypertension. Hydrochlorothiazide (HCTZ), one of the most commonly used medications to treat hypertension, has variable efficacy. The renal epithelial sodium channel (ENaC) provides a mechanism for fine-tuning sodium excretion, and is a major regulator of blood pressure homeostasis. DOT1L, MLLT3, SIRT1, and SGK1 encode genes in a pathway that controls methylation of the histone H3 globular domain at lysine 79 (H3K79), thereby modulating expression of the ENaCα subunit. This study aimed to determine the role of variation in these regulatory genes on blood pressure response to HCTZ, and secondarily, untreated blood pressure.Methods: We investigated associations between genetic variations in this candidate pathway and HCTZ blood pressure response in two separate hypertensive cohorts (clinicaltrials.gov NCT00246519 and NCT00005520). In a secondary, exploratory analysis, we measured associations between these same genetic variations and untreated blood pressure. Associations were measured by linear regression, with only associations with P ≤ 0.01 in one cohort and replication by P ≤ 0.05 in the other cohort considered significant.Results: In one cohort, a polymorphism in DOT1L (rs2269879) was strongly associated with greater systolic (P = 0.0002) and diastolic (P = 0.0016) blood pressure response to hydrochlorothiazide in Caucasians. However, this association was not replicated in the other cohort. When untreated blood pressure levels were analyzed, we found directionally similar associations between a polymorphism in MLLT3 (rs12350051) and greater untreated systolic (P < 0.01 in both cohorts) and diastolic (P < 0.05 in both cohorts) blood pressure levels in both cohorts. However, when further replication was attempted in a third hypertensive cohort and in smaller, normotensive samples, significant associations were not observed.Conclusions: Our data suggest polymorphisms in DOT1L, MLLT3, SIRT1, and SGK1 are not likely associated with blood pressure response to HCTZ. However, a possibility exists that rs2269879 in DOT1L could be associated with HCTZ response in Caucasians. Additionally, exploratory analyses suggest rs12350051 in MLLT3 may be associated with untreated blood pressure in African-Americans. Replication efforts are needed to verify roles for these polymorphisms in human blood pressure regulation.

AB - Background: Nearly one-third of the United States adult population suffers from hypertension. Hydrochlorothiazide (HCTZ), one of the most commonly used medications to treat hypertension, has variable efficacy. The renal epithelial sodium channel (ENaC) provides a mechanism for fine-tuning sodium excretion, and is a major regulator of blood pressure homeostasis. DOT1L, MLLT3, SIRT1, and SGK1 encode genes in a pathway that controls methylation of the histone H3 globular domain at lysine 79 (H3K79), thereby modulating expression of the ENaCα subunit. This study aimed to determine the role of variation in these regulatory genes on blood pressure response to HCTZ, and secondarily, untreated blood pressure.Methods: We investigated associations between genetic variations in this candidate pathway and HCTZ blood pressure response in two separate hypertensive cohorts (clinicaltrials.gov NCT00246519 and NCT00005520). In a secondary, exploratory analysis, we measured associations between these same genetic variations and untreated blood pressure. Associations were measured by linear regression, with only associations with P ≤ 0.01 in one cohort and replication by P ≤ 0.05 in the other cohort considered significant.Results: In one cohort, a polymorphism in DOT1L (rs2269879) was strongly associated with greater systolic (P = 0.0002) and diastolic (P = 0.0016) blood pressure response to hydrochlorothiazide in Caucasians. However, this association was not replicated in the other cohort. When untreated blood pressure levels were analyzed, we found directionally similar associations between a polymorphism in MLLT3 (rs12350051) and greater untreated systolic (P < 0.01 in both cohorts) and diastolic (P < 0.05 in both cohorts) blood pressure levels in both cohorts. However, when further replication was attempted in a third hypertensive cohort and in smaller, normotensive samples, significant associations were not observed.Conclusions: Our data suggest polymorphisms in DOT1L, MLLT3, SIRT1, and SGK1 are not likely associated with blood pressure response to HCTZ. However, a possibility exists that rs2269879 in DOT1L could be associated with HCTZ response in Caucasians. Additionally, exploratory analyses suggest rs12350051 in MLLT3 may be associated with untreated blood pressure in African-Americans. Replication efforts are needed to verify roles for these polymorphisms in human blood pressure regulation.

KW - Blood pressure

KW - DOT1L

KW - Histone methylation

KW - Hydrochlorothiazide

KW - Hypertension

KW - MLLT3

KW - Pharmacogenetics

KW - Pharmacogenomics

KW - SGK1

KW - SIRT1

UR - http://www.scopus.com/inward/record.url?scp=84862828371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862828371&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-10-56

DO - 10.1186/1479-5876-10-56

M3 - Article

VL - 10

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 56

ER -